Products

Linifanib ABT-869 796967-16-3

1.Inquiries will be replied within 24 hours
2.We could supply various packages as you required
3.To protect the profit of our agents, price will not show on website, please send inquiries to get the price.
4.Fast delivery, goods arrive your office within 3 to 5 days
5.Please click "Inquiry" or "Email" below to get the price
 
Synonyms
Appearance
Chemical Formula
C21H18FN5O
Solubility
Molecular Weight
375.41
Storage and Stability
in stock
CAS No.
796967-16-3
Purity
98%+
Introduction
Linifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDRCSF-1RFlt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent cancer cells (i.e. FLT3). Phase 3.

Linifanib shows inhibitory to Kit, PDGFRβ and Flt4 with IC50 of 14 nM, 66 nM and 190 nM in kinases assay. Linifanib also inhibits ligand-induced KDR, PDGFRβ, Kit, and CSF-1R phosphorylation with IC50 of 2 nM, 2 nM, 31 nM and 10 nM at cellular level and this cellular potency could be affected by serum protein. Linifanib suppresses VEGF-stimulated HUAEC proliferation with IC50 of 0.2 nM. While Linifanib has weak activity against tumor cells which are not induced by VEGF or PDGF, except for MV4-11 leukemia cells (with constitutively active form of Flt3) with IC50 of 4 nM. Linifanib could cause a decrease in S and G2-M phases with a corresponding increase in the sub-G0-G1 apoptotic population in MV4-11 cells. Linifanib binds to the ATP-binding site of CSF-1R with Ki of 3 nM. Linifanib (10 nM) exhibits a reduced phosphorylation of Akt at Ser473 and decreased phosphorylation of GSK3βat Ser9 in Ba/F3 FLT3 ITD cell lines. 

Thank you for your company product support!

CAS No. :

Product Name :

Number :

Your name:
*

Phone:

Email:
*

The company or laboratory name:
*